Title:
COMPOSITION FOR SUPPRESSING RESISTANCE TO EGFR-TARGETING AGENT
Document Type and Number:
WIPO Patent Application WO/2017/171373
Kind Code:
A2
Abstract:
The present invention relates to methods for controlling resistance or sensitivity to an epidermal growth factor receptor (EFGR)-targeting agent through a peptide binding specifically to Neuropilin 1. In addition, the present invention relates to a composition for controlling resistance or sensitivity to an EGFR-targeting agent by co-administering a fusion antibody in which a peptide binding specifically to Neuropilin 1 is fused to an EGFR-targeting antibody, and a constant region of the heavy chain in an antibody in which the EGFR-targeting agent is fused to the peptide. Further, the fusion antibody in which a peptide binding specifically to Neuropilin 1 is fused to an EGFR-targeting antibody in accordance with the present invention allows for overcoming resistance to EGFR-targeting antibodies in pancreatic cancer. Furthermore, the fusion antibody in which a peptide binding specifically to Neuropilin 1 is fused to an EGFR-targeting antibody allows for overcoming resistance to EGFR-targeting antibodies even in the lung cancer that is resistant to EGFR-targeting antibodies. Hence, the peptide binding specifically to Neuropilin 1 in accordance with the present invention is expected to have high effects of treating various tumors resistant to EGFR-targeting agents.
Inventors:
KIM YONG SUNG (KR)
KIM YE JIN (KR)
KIM YE JIN (KR)
Application Number:
PCT/KR2017/003365
Publication Date:
October 05, 2017
Filing Date:
March 28, 2017
Export Citation:
Assignee:
AJOU UNIV INDUSTRY-ACADEMIC COOP FOUND (KR)
International Classes:
A61K38/08; A61K39/395; A61K38/10; A61K47/50
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF: